AnaptysBio Inc (ANAB) Shares Sold by Kennedy Capital Management Inc.
Kennedy Capital Management Inc. lessened its holdings in AnaptysBio Inc (NASDAQ:ANAB) by 49.1% during the 4th quarter, HoldingsChannel reports. The firm owned 49,966 shares of the biotechnology company’s stock after selling 48,167 shares during the quarter. Kennedy Capital Management Inc.’s holdings in AnaptysBio were worth $5,033,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also made changes to their positions in ANAB. OppenheimerFunds Inc. purchased a new stake in shares of AnaptysBio in the fourth quarter valued at about $106,701,000. BlackRock Inc. lifted its holdings in shares of AnaptysBio by 104.1% in the fourth quarter. BlackRock Inc. now owns 1,393,305 shares of the biotechnology company’s stock valued at $140,334,000 after purchasing an additional 710,574 shares in the last quarter. Citadel Advisors LLC purchased a new stake in shares of AnaptysBio in the third quarter valued at about $20,406,000. VHCP Management II LLC purchased a new stake in shares of AnaptysBio in the third quarter valued at about $5,856,000. Finally, Kornitzer Capital Management Inc. KS purchased a new stake in shares of AnaptysBio in the fourth quarter valued at about $12,767,000.
AnaptysBio Inc (NASDAQ:ANAB) opened at $116.87 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 10.77 and a current ratio of 17.93. AnaptysBio Inc has a 52-week low of $18.15 and a 52-week high of $134.00.
ANAB has been the topic of several recent research reports. Robert W. Baird reaffirmed a “buy” rating and issued a $144.00 price target (up previously from $81.00) on shares of AnaptysBio in a report on Friday, January 19th. Zacks Investment Research downgraded shares of AnaptysBio from a “buy” rating to a “hold” rating in a report on Tuesday, January 2nd. Royal Bank of Canada upped their price target on shares of AnaptysBio to $108.00 and gave the company an “outperform” rating in a report on Monday, December 18th. Credit Suisse Group set a $135.00 price target on shares of AnaptysBio and gave the company an “outperform” rating in a report on Tuesday, January 23rd. Finally, SunTrust Banks upped their price target on shares of AnaptysBio from $115.00 to $162.00 and gave the company a “buy” rating in a report on Thursday, February 15th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. AnaptysBio presently has a consensus rating of “Buy” and a consensus price target of $129.67.
AnaptysBio, Inc is a clinical-stage biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Want to see what other hedge funds are holding ANAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AnaptysBio Inc (NASDAQ:ANAB).
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.